Autoimmune Bullous Diseases Research Center, Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
JAMA Dermatol. 2014 Mar;150(3):266-72. doi: 10.1001/jamadermatol.2013.8175.
Recently, the clinical pemphigus disease activity indexes of Pemphigus Disease Area Index (PDAI), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS), and Pemphigus Vulgaris Activity Score (PVAS) were validated to correlate with physician global assessment. The antidesmoglein (anti-Dsg) autoantibodies are known to correlate mostly with pemphigus disease activity. The correlation between these indexes and anti-Dsg1 and anti-Dsg3 enzyme-linked immunosorbent assay values has not been previously evaluated.
To evaluate the PDAI, ABSIS, and PVAS in a large number of patients with pemphigus vulgaris and to compare the interrater reliability of these indexes and the convergent validity according to anti-Dsg values.
DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional study was performed in 2012 in a referral university center for autoimmune bullous diseases. One hundred patients with confirmed diagnoses of pemphigus vulgaris and clinical pemphigus lesions (mean [SD] age, 43.3 [1.7] years; age range, 14-77 years; female-male ratio, 1:3) were studied. Three dermatologists familiar with immunobullous diseases and the indexes rated the patients.
All 100 patients were evaluated with the PDAI, ABSIS, and PVAS. Three dermatologists independently rated all 3 indexes for each of the patients on the same day. Serum anti-Dsg1 and anti-Dsg3 enzyme-linked immunosorbent assay values were measured simultaneously.
Analyses of interrater reliabilities, convergent validities according to anti-Dsg titers, correlation between the distribution and types of lesions with disease activity, predictors of higher titers of antibody (multiple regression analysis), and cutoff values of measures for 2 titers of anti-Dsg with optimal area under the curve, sensitivity, and specificity were performed.
The interrater reliabilities were highest for the PDAI, followed by the ABSIS and the PVAS (intraclass correlation coefficients of 0.98 [95% CI, 0.97-0.98], 0.97 [95% CI, 0.96-0.98], and 0.93 [95% CI, 0.90-0.95], respectively). The convergent validity was highest for the PDAI, followed by the PVAS and the ABSIS (Spearman ρ = 0.67, 0.52, and 0.33, respectively). Head, neck, and trunk involvement were predictors of higher titers of anti-Dsg1.
Among the 3 studied indexes, the PDAI had the highest validity and is recommended for use in multicenter studies for rare diseases, such as pemphigus vulgaris.
最近,天疱疮疾病活动指数(PDAI)、自身免疫性大疱性皮肤病严重程度评分(ABSIS)和寻常型天疱疮活动评分(PVAS)的临床天疱疮疾病活动指数已被验证与医生整体评估相关。众所周知,抗桥粒芯糖蛋白(anti-Dsg)自身抗体主要与天疱疮疾病活动相关。这些指标与抗 Dsg1 和抗 Dsg3 酶联免疫吸附测定值之间的相关性尚未被评估。
评估大量寻常型天疱疮患者的 PDAI、ABSIS 和 PVAS,并比较这些指标的内部信度和根据抗 Dsg 值的收敛效度。
设计、地点和参与者:这是一项 2012 年在自身免疫性大疱性疾病转诊中心进行的横断面研究。对 100 名经临床确诊为寻常型天疱疮且存在天疱疮皮损的患者(平均[标准差]年龄为 43.3[1.7]岁;年龄范围为 14-77 岁;男女比例为 1:3)进行了研究。3 名熟悉免疫性大疱病和这些指标的皮肤科医生对患者进行了评估。
对所有 100 名患者进行了 PDAI、ABSIS 和 PVAS 评估。3 名皮肤科医生在同一天对所有患者的 3 项指标进行了独立评估。同时测定血清抗 Dsg1 和抗 Dsg3 酶联免疫吸附试验值。
分析了内部信度、根据抗 Dsg 滴度的收敛效度、皮损分布和类型与疾病活动的相关性、抗体高滴度的预测因素(多元回归分析),以及最佳曲线下面积、敏感性和特异性的 2 种抗 Dsg 测量值的截断值。
PDAI 的内部信度最高,其次是 ABSIS 和 PVAS(组内相关系数分别为 0.98[95%CI,0.97-0.98]、0.97[95%CI,0.96-0.98]和 0.93[95%CI,0.90-0.95])。PDAI 的收敛效度最高,其次是 PVAS 和 ABSIS(Spearman ρ值分别为 0.67、0.52 和 0.33)。头颈部和躯干部皮损是抗 Dsg1 高滴度的预测因素。
在这 3 项研究指标中,PDAI 的有效性最高,建议在罕见疾病(如寻常型天疱疮)的多中心研究中使用。